Αποτελέσματα Αναζήτησης
1 ημέρα πριν · Contractures in the fingers caused by Dupuytren disease are commonly treated with either limited fasciectomy or injection of collagenase. Evidence to guide the choice of treatment is limited, but ...
27 Ιαν 2022 · Operative treatments include percutaneous needle fasciotomy (PNF), open fasciotomy (OF), Clostridium collagenase histolyticum (CCH) injections, limited fasciectomy (LF) and dermofasciectomy (DF). The various methods of DD treatment are reviewed. Results: We summarize the highlights of each treatment option as well as the strengths and weaknesses.
A systematic review of non-surgical treatments for early-stage Dupuytren’s disease identified various pharmacological treatments (oral, intramuscular, topical or intralesional steroids; vitamin E, furazolidone, aminosyn (an amino acid solution), hyperbaric oxygen), radiotherapy and physical therapies (ultrasound, splinting, frictional massage ...
29 Απρ 2022 · The consensus is that Dupuytren's disease does not need treatment until contractures develop to greater than 30° at the metacarpophalangeal and 15° at the proximal interphalangeal joint.1 Treatment commonly consists of limited fasciectomy to remove the cord, needle aponeurotomy, or collagenase injection to weaken and break the cord.
There are different treatment options for Dupuytren s Disease, but high level evidence of their effectiveness is limited. In this chapter, we give an overview of the different treatment options with the best available evidence (level 3 or greater). Dupuytren s Disease (DD) is a bromatosis of the
15 Νοε 2011 · There are different treatment options for Dupuytren’s Disease, but high level evidence of their effectiveness is limited. In this chapter, we give an overview of the different treatment options with the best available evidence (level 3 or greater).
29 Απρ 2022 · Treatments for late-stage disease all have limitations, and there is no approved treatment for early-stage disease. We identified tumour necrosis factor as a therapeutic target in Dupuytren's disease, and in a dose ranging trial found 40 mg adalimumab in 0·4 mL to be most efficacious.
